DOI: 10.1161/circ.148.suppl_1.17501 ISSN: 0009-7322

Abstract 17501: Initial Experience With a Novel Transcatheter Aortic Valve With Open-Cell Design and Staged Delivery for Challenging Anatomies in a Developing Country

Marcos Antônio Marino, Roberto Luiz Marino, Bárbara C Marino, Walter Rabelo, Hugo A Mariano de Azevedo Frota, Evandro Vitor Andrade, Alexandre V Vasconcellos, Luis Eduardo D Couto, Jessica De Paula, Rodrigo C Bernardes, Fernando Antônio R Reis Filho, Alexandre Henrique Cobucci Santana, Bruno R Nascimento
  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Introduction: Overcoming challenges of transcatheter aortic valve (TAVI) implantation, as coronary access, conduction disturbances and paravalvular leak are goals of device development. We aimed to describe the initial experience with a recently-approved self-expandable bioprosthetic valve, with supravalvular leaflets, a novel open-cell design and 2-stage deployment, in terms of efficacy and safety.

Methods: Consecutive patients with aortic valve (AV) stenosis and indication for TAVI with favorable anatomy for self-expandable prostheses were prospectively enrolled in a high-volume center in Belo Horizonte, Brazil. Demographic, clinical and procedural data were collected in an online dedicated database (Coreware, RIBAC). Echocardiographic and CT-angio measurements were performed by 2 experts with proprietary software (Phillips Heart Navigator). Outcomes were prospectively collected.

Results: At total, 23 patients eligible for the Acurate Neo/Neo2 TAVI were enrolled, being 15 men, mean age of 82±6 years (69 - 93). Hypertension was present in 20, diabetes in 8 and dyslipidemia in 17, and all were severely symptomatic, being 20 in functional class 3. The STS-score (morbi-mortality) was high: 19±6%. The mean AV area on echo was 0.7±0.2 cm 2 , with mean gradient of 44±15 mmHg. In CT-angio, the median calcium score was 2284, mean annular perimeter was 72±5 mm, and the height of the right and left coronary ostia were 15.2±2.6 mm and 11.9±3.2 mm (<10 mm in 5 cases). All implants were transfemoral (14F) and with general anesthesia, given the high-risk profile. Pre-dilation was performed in 20 (91%) and the TAVI was deployed without repositioning in all cases, with no coronary compromise. Post-dilation was required in 13 cases, being 11 due to mild and 2 due to moderate paravalvular leak: all regressed to trivial. Vascular complications requiring surgery occurred in 1 case, and 1 (4%) patient underwent permanent pacing. All patients were discharged home, with a mean AV gradient of 9.7±3.7 mmHg.

Conclusion: The initial experience in Brazil with the novel Acurate Neo/Neo2 prosthesis was promising, with high success rates in challenging anatomical scenarios, and low rates of pacemaker implantation and no occurrence of coronary obstruction or significant leak.

More from our Archive